Vanguard Group Inc. Purchases 182,183 Shares of Denali Therapeutics Inc. $DNLI

Vanguard Group Inc. lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 1.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,992,918 shares of the company’s stock after buying an additional 182,183 shares during the quarter. Vanguard Group Inc. owned approximately 8.20% of Denali Therapeutics worth $174,137,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of DNLI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Denali Therapeutics by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock worth $1,210,000 after purchasing an additional 3,432 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Denali Therapeutics by 58.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock valued at $22,732,000 after acquiring an additional 614,555 shares during the period. Empowered Funds LLC boosted its holdings in shares of Denali Therapeutics by 11.0% in the 1st quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock valued at $281,000 after acquiring an additional 2,052 shares during the last quarter. Woodline Partners LP raised its holdings in shares of Denali Therapeutics by 13.5% during the first quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock worth $1,543,000 after purchasing an additional 13,517 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in shares of Denali Therapeutics by 6.7% during the second quarter. Envestnet Asset Management Inc. now owns 33,538 shares of the company’s stock worth $469,000 after purchasing an additional 2,108 shares during the last quarter. 92.92% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. BTIG Research increased their price target on Denali Therapeutics from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday. Morgan Stanley restated an “overweight” rating and set a $40.00 price target on shares of Denali Therapeutics in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. UBS Group began coverage on Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating on the stock. Finally, JPMorgan Chase & Co. increased their price target on Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.45.

Denali Therapeutics Trading Down 0.8%

Shares of DNLI opened at $21.00 on Tuesday. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $23.77. The stock has a market cap of $3.33 billion, a PE ratio of -7.07 and a beta of 1.02. The firm’s fifty day moving average is $19.16 and its two-hundred day moving average is $17.17. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same period last year, the firm earned ($0.67) EPS. Research analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Insider Activity

In other Denali Therapeutics news, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the sale, the chief executive officer directly owned 296,833 shares in the company, valued at $4,897,744.50. This represents a 10.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. The trade was a 5.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 12.50% of the stock is currently owned by corporate insiders.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.